Dublin, OH (July 15, 2013) – Biosortia Pharmaceuticals announced today a research agreement with AstraZeneca to screen Biosortia’s library of unique natural products derived from aquatic microbial consortia for evaluation against AstraZeneca’s therapeutic targets. The agreement includes the evaluation of partially refined mixtures as well as individual compounds. The aquatic environment is a rich source of
By Emily Mullin, (July 09, 2013) – At a time when most of the biopharma industry has focused its preclinical research on screening synthetic compounds for their drug potential, Biosortia Pharmaceuticals is going back to nature to find promising compounds at the early stage of discovery. Dublin, OH-based startup Biosortia is harvesting the communities, or consortia,
